



- **Headquarters:** Hangzhou, China
- Dedicated to establishing a globally leading biologics development platform based on viral recombinant technology.
- Seeking global partners to develop, register and commercialize this product.

Company Profile


- Through advancements in viral-attenuation techniques, targeted gene delivery systems, and vector-controllability mechanisms, DIFF's platform—built upon recombinant virus technology—enables broad therapeutic applications across vaccines, oncology treatments, gene therapy approaches, and antiviral drug development.
- DIFF's IP portfolio comprises **80+ patent applications**, with **10+ international PCT applications**.

Product Overview

- Safety Breakthrough:** Eliminates innate VSV neurotoxicity, enabling safe systemic administration
- Potent Oncolysis:** Rapid replication and potent lytic activity drive fast tumor clearance
- Immune Synergy:** Achieves **complete tumor eradication** and long-term, tumor-free survival in animal models
- Platform Advantages:** High yield, low cost, scalable manufacturing, and **adaptable across multiple cancer indications**

Unlocking a Billion-Dollar Blue Ocean Market


- The global oncolytic virus market was valued at **USD 87.1 million in 2024** and is projected to surge to **USD 7.5 billion by 2030**.
- To date, **only four oncolytic virus products have received regulatory approval**, highlighting substantial unmet needs and opportunities for next-generation virotherapies.



DIFF-OV, built on a VSV vector, offers several key advantages:

- **Rapid *in vivo* replication** that elicits a potent immune response, enabling swift tumor control.
- **Robust oncolytic activity** with the flexibility to combine with immunomodulatory molecules to further enhance anti-tumor efficacy.


Global Oncolytic Virus Market Size(2024-2030)



Data Source: Frost & Sullivan Analysis


Product Highlights

In Vitro Antitumor Activity




Potent cytotoxic activity across multiple tumor cell lines *in vitro*

Intracranial Injection – Body Weight Changes




All inoculated mice achieved 100% survival with no significant weight loss, indicating that DIFF-OV exhibits no neurotoxicity.

Intracranial Injection – Survival Rate




Efficacy Studies in Immunocompetent Mouse Model



In CT26 syngeneic model, DIFF-OV achieved complete tumor regression in 4/6 treated mice; no tumor recurrence following rechallenge at 8 weeks.

Efficacy Studies in Human Colorectal Cancer Xenograft Model



In HT-29 model, DIFF-OV effectively suppressed tumor growth in all treated mice (9/9).